Skip to main content

Table 1 Ongoing clinical trials using AAT in young patients with type 1 diabetes

From: Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?

NCT Phase Age range (years) Source/dose of AAT (mg)
01304537 II 10 to 25 Glassia®/40-60-80
01319331 I 6 to 45 Aralast NP
01183468 II 8 to 35 Aralast NP